Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

306

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

December 31, 2006

Conditions

Parkinson's Disease

Interventions

DRUG

rasagiline mesylate

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00203138 - Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter